|
|
Article: Cytoclonal Develops New Lead Compounds Against the Common Cold Virus; Company Designs Rhinovirus Inhibitors.
- Article from:
- PR Newswire
- Article date:
- January 31, 2000
CopyrightCOPYRIGHT 2000 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DALLAS, Jan. 31 /PRNewswire/ -- Cytoclonal Pharmaceutics Inc. (Nasdaq: CYPH, CYPHW, CYPHZ), announced today the development of several active lead compounds to inhibit Rhinoviruses the most frequent cause of the common cold. The lead compounds inhibit the Rhinovirus 3C Protease and were designed for broad antiviral activity, low toxicity and reduced resistance. The lead molecules provide protection of human cells in culture against several types of Rhinovirus. One class of compound showed minimum toxicity in animal studies.
The compounds were designed using the company's novel drug design technology called Quantum Core Technology(TM) (QCT(TM)) under the ...